Advances in Anticancer Agents in Medicinal Chemistry

Volume: 1

Casein Kinase 2 (CK2) Inhibitors: Emerging Anticancer Therapeutic Agents?

Author(s): Giorgio Cozza and Stefano Moro

Pp: 3-42 (40)

DOI: 10.2174/9781608054930113010004

* (Excluding Mailing and Handling)

Abstract

Protein kinase CK2 (Casein Kinase 2) is an ubiquitous, highly pleiotropic, constitutive active and essential protein kinase, with both cytosolic and nuclear localization in most mammalian cells. The holoenzyme is generally composed of two catalytic (alpha and/or alpha') and two regulatory (beta) subunits, but the free alpha/alpha' subunits are catalytically active by themselves and can be present in cells under some circumstances. CK2 catalyzes the phosphorylation of more than 300 substrates characterized by multiple acidic residues surrounding the phosphor-acceptor amino acid and, consequently, it plays a key role in several physiological and pathological processes. It’s abnormally high constitutive activity is implicated in several diseases and neoplasia, and a number of ATP competitive inhibitors of CK2 with micromolar and nanomolar in vitro activity, display a pro-apoptotic effect also in cell.


Keywords: CK2, protein kinases, inhibitors, cancer, neurodegenerative diseases, viral infections

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy